News

Galectin Therapeutics‘ experimental medication belapectin may help reduce liver scarring, or fibrosis, and lower the risk of blood vessel complications in people with metabolic-associated…

Therapy using stem cells derived from donor umbilical cords may help improve outcomes in infants with biliary atresia who have undergone standard Kasai surgery,…

New modeling data predict that bemnifosbuvir and ruzasvir, an experimental combination treatment being developed by Atea Pharmaceuticals for chronic hepatitis C, may…

Liscure Biosciences has launched a Phase 2 clinical trial to test whether its experimental probiotic LB-P8 can improve gut health and reduce liver inflammation…

Treatment with melatonin, a naturally occurring hormone best known for regulating sleep, may help reduce liver injury caused by cholestasis, according to a study…

Long-term treatment with Rezdiffra (resmetirom) reduces liver scarring and other signs of advanced disease in adults with high-risk compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis…

An experimental antisense oligonucleotide (ASO) therapy designed to boost production of the Jagged-1 protein — which is known as Jag1 in mice and JAG1 in…

PBGENE-HBV, Precision BioSciences’ experimental gene-editing therapy for chronic hepatitis B, showed antiviral activity across three doses, with the highest dose approaching the benchmark…

Up to three years of treatment with Gilead Sciences‘ Livdelzi (seladelpar) results in sustained reductions in itching and biomarkers of liver injury in adults…

HU6, an experimental oral therapy from Rivus Pharmaceuticals, safely and effectively reduced liver fat and led to fat-selective weight loss in adults with metabolic…